Oculis plans R&D day to highlight late-stage drug pipeline
OCS•Oculis will hold an in-person and virtual R&D Day on December 8, 2026, to discuss licaminlimab’s registrational trial in dry eye disease and Privosegtor’s development for optic neuritis and acute multiple sclerosis relapses.
1. R&D day agenda
Oculis will host the event at the St. Regis New York, starting at 10 a.m. EST. Presentations will cover licaminlimab’s registrational trial in dry eye disease and Privosegtor’s development for optic neuritis and acute multiple sclerosis relapses.
